列线图
腺癌
基因签名
比例危险模型
肿瘤科
肺癌
内科学
单变量
间质细胞
基因
医学
单变量分析
多元分析
生物
癌症
多元统计
基因表达
遗传学
统计
数学
作者
Jiaqi Huang,Jingyuan Zhang,Fanqin Zhang,Shan Lu,Siyu Guo,Rui Shi,Yiyan Zhai,Yifei Gao,Xiaoyu Tao,Zhe Jin,Leiming You,Jiarui Wu
标识
DOI:10.1016/j.compbiomed.2023.107402
摘要
Lung adenocarcinoma (LUAD) is the most prevalent subtype of non-small cell lung cancer. Additionally, disulfidptosis, a newly discovered type of cell death, has been found to be closely associated with the onset and progression of tumors. The study first identified genes related to disulfidptosis through correlation analysis. These genes were then screened using univariate cox regression and LASSO regression, and a prognostic model was constructed through multivariate cox regression. A nomogram was also created to predict the prognosis of LUAD. The model was validated in three independent data sets: GSE72094, GSE31210, and GSE37745. Next, patients were grouped based on their median risk score, and differentially expressed genes between the two groups were analyzed. Enrichment analysis, immune infiltration analysis, and drug sensitivity evaluation were also conducted. In this study, we examined 21 genes related to disulfidptosis and developed a gene signature that was found to be associated with a poorer prognosis in LUAD. Our model was validated using three independent datasets and showed AUC values greater than 0.5 at 1, 3, and 5 years. Enrichment analysis revealed that the disulfidptosis-related genes signature had a multifaceted impact on LUAD, particularly in relation to tumor development, proliferation, and metastasis. Patients in the high-risk group exhibited higher tumor purity and lower stromal score, ESTIMATE score, and Immune score. This study constructed a gene signature related to disulfidptosis in lung adenocarcinoma and analyzed its impact on the disease and its association with the tumor microenvironment. The findings of this research provide valuable insights into the understanding of lung adenocarcinoma and could potentially lead to the development of new treatment strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI